Assembly Biosciences, Inc. financial data

Symbol
ASMB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Two Tower Place, 7 Th Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
VENTRUS BIOSCIENCES INC (to 7/11/2014)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 327 % -53.5%
Debt-to-equity 182 % +803%
Return On Equity -122 % -15.9%
Return On Assets -43.1 % +50.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.35M shares -87.9%
Common Stock, Shares, Outstanding 6.35M shares -87.9%
Entity Public Float 60M USD -40.3%
Common Stock, Value, Issued 6K USD -88.5%
Weighted Average Number of Shares Outstanding, Basic 5.64M shares +29.6%
Weighted Average Number of Shares Outstanding, Diluted 5.64M shares +29.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 50M USD -19.5%
General and Administrative Expense 22M USD +3.14%
Operating Income (Loss) -50.5M USD +39.4%
Nonoperating Income (Expense) 5.36M USD +163%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.7M USD +36.4%
Income Tax Expense (Benefit) 406K USD
Net Income (Loss) Attributable to Parent -45.6M USD +44%
Earnings Per Share, Basic -8.68 USD/shares +71.5%
Earnings Per Share, Diluted -8.68 USD/shares +71.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.2M USD -11.2%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 113M USD +76.2%
Property, Plant and Equipment, Net 349K USD -35.5%
Operating Lease, Right-of-Use Asset 1.73M USD +6.65%
Other Assets, Noncurrent 312K USD -6.02%
Assets 115M USD +73.2%
Accounts Payable, Current 801K USD -11.4%
Employee-related Liabilities, Current 2.79M USD -28.7%
Accrued Liabilities, Current 3.59M USD -14.4%
Contract with Customer, Liability, Current 33.1M USD
Liabilities, Current 41.3M USD +367%
Contract with Customer, Liability, Noncurrent 38.9M USD +1324%
Operating Lease, Liability, Noncurrent 451K USD +605%
Liabilities 80.6M USD +594%
Accumulated Other Comprehensive Income (Loss), Net of Tax -293K USD +9.85%
Retained Earnings (Accumulated Deficit) -806M USD -6%
Stockholders' Equity Attributable to Parent 34.7M USD -36.9%
Liabilities and Equity 115M USD +73.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.4M USD +21.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +72.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 6.35M shares -87.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.09M USD +87.8%
Deferred Tax Assets, Valuation Allowance 202M USD +10%
Deferred Tax Assets, Gross 203M USD +9.88%
Operating Lease, Liability 2.34M USD -32.4%
Payments to Acquire Property, Plant, and Equipment 14K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.6M USD +43.5%
Lessee, Operating Lease, Liability, to be Paid 2.57M USD -29.7%
Property, Plant and Equipment, Gross 595K USD -75.5%
Operating Lease, Liability, Current 1.3M USD -23.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.17M USD +1508%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD -60.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD +16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 37K USD +270%
Deferred Tax Assets, Operating Loss Carryforwards 148M USD +2.74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 4.5M USD +16.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 32K USD -74.2%
Deferred Tax Assets, Net of Valuation Allowance 646K USD -20.3%
Share-based Payment Arrangement, Expense 3.67M USD -44.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%